A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

This is a Phase II, single-Arm, prospective study of neoadjuvant Icotinib with chemotherapy for the treatment of patients with epidermal growth factor receptor mutation positive, resectable for stage II to IIIB(N2) Non-small Cell Lung Cancer

Trial Details

NCT ID
NCT05104788
Phase
PHASE2
Sponsor
Peking University Cancer Hospital & Institute
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Icotinib
  • Cisplatin
  • Carboplatin
  • Pemetrexed
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been i…
  • Male or female, at least 18 years of age.
  • Histologically or cytologically documented lung adenocarcinoma within 60 days prior to study enrollment.
  • Clinical stage IIA/IIB/IIIA/IIIB assessed by EBUS-TBNA or PET(positron emission tomography)/CT can be resected.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →